Shareholders in the Nasdaq-listed German company, which is backed by billionaire investor and PayPal co-founder Peter Thiel, ...

Meanwhile, BioNTech itself bought into the category with its takeover of BNT327's developer Biotheus unit last year for what ...

According to AZ, SERENA-6 is also the first pivotal trial to show the value of measuring circulating tumour DNA (ctDNA) to ...

23andMe has said it wants to allow new bids by both parties with a deadline of 12th June, according to a Financial Times ...

Hudson has previously said he was looking for M&A deals this year to shore up its already-strong position in immunology, ...

Recent history should have the pharmaceutical industry questioning some of its fundamental assumptions. The COVID-19 pandemic led to skyrocketing demand for some products while simultaneously ...

The FDA has instructed Pfizer and Moderna to add stronger warnings to the labels of their COVID-19 vaccines about the risk of cardiotoxicity in some patients, citing a recent study and new data.

To my ears, the noise about patient centricity has deadened slightly. Dedicated patient centricity teams in some companies have been and gone (or at least marginalised), and everyone seems keener ...

If pharma wants its products to fulfil their life-enhancing potential, then, it needs to do everything it can to support the patients in their management journey. Outcomes-based payments With the ...

This year, the predicted flurry of merger and acquisition (M&A) activity might not have materialised. However, as we near the end of the year, there were some big moves. M&A is an integral part of ...

In the pharmaceutical research field, the journey from laboratory to pharmacy shelf is fraught with challenges, such as the high failure rates and increasing costs of clinical trials. Significant ...

Are you looking to solve challenges with current RNA therapeutics, such as the degradation of RNA by RNAses, the difficulty of RNA crossing the cell membrane by diffusion and the immunogenicity ...